Mohammad Afshar is the founder and CEO Ariana Pharma, a leading Artificial Intelligence (AI) drug development company based in Paris, FR, and Boston, USA. Ariana specializes in precisionmedicine clinical trials, translating multi-omic data into innovative clinical development plans and regulatory approvals.
Prior to Ariana, Mohammad was a founder and the Director of Drug Design at RiboTargets, Cambridge, UK. He set up and managed the platform which discovered and successfully licensed several novel therapeutic molecules. Before joining RiboTargets he held several academic positions including at the Department of Chemistry of the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), a PhD in structural biochemistry and a Habilitation Doctorate (HDR) from the Faculty of Medicine of the University of Montpellier, France. Since 2014, he is on the investment advisory board of Seventure Partners VC fund.